论文部分内容阅读
在过去的20多年中,CIK细胞已逐步从实验室研究走向临床应用研究并展现了一定的抗瘤效果。然而,CIK细胞存在缺乏抗原特异性、靶向性不足、体内存活时间短等问题限制了其在临床上的应用。随着嵌合抗原受体(chimeric antigen receptor,CAR)修饰的T细胞(CAR-T)技术的兴起,CIK细胞的CAR修饰潜力也倍受关注。本文就CAR-CIK细胞的构建思路、效应细胞来源和简化治疗优势、基础研究和临床转化现状以及目前CAR-CIK面临的瓶颈问题等的研究进展作一综述。
In the past 20 years, CIK cells have been gradually moving from laboratory research to clinical application and show some anti-tumor effect. However, the lack of antigen-specific CIK cells, lack of targeting, short survival time in vivo and other issues have limited its clinical application. With the rise of chimeric antigen receptor (CAR) modified T cell (CAR-T) technology, the potential of CAR modification in CIK cells has drawn much attention. This article reviews the research progress of CAR-CIK cell construction, the origin of effector cells, the advantages of simplified treatment, the status quo of basic research and clinical transformation, and the bottleneck facing CAR-CIK.